Format

Send to

Choose Destination
Melanoma Res. 2019 Apr;29(2):109-118. doi: 10.1097/CMR.0000000000000535.

Melanoma vaccines: clinical status and immune endpoints.

Author information

1
Departments of Immunology.
2
Medicine.
3
Surgery.
4
Clinical and Translational Science, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Abstract

It has been known for decades that the immune system can be spontaneously activated against melanoma. The presence of tumor infiltrating lymphocytes in tumor deposits is a positive prognostic factor. Cancer vaccination includes approaches to generate, amplify, or skew antitumor immunity. To accomplish this goal, tested approaches involve administration of tumor antigens, antigen presenting cells or other immune modulators, or direct modulation of the tumor. Because the success of checkpoint blockade can depend in part on an existing antitumor response, cancer vaccination may play an important role in future combination therapies. In this review, we discuss a variety of melanoma vaccine approaches and methods to determine the biological impact of vaccination.

PMID:
30802228
PMCID:
PMC6392068
[Available on 2020-04-01]
DOI:
10.1097/CMR.0000000000000535

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center